Pickart L, Vasquez-Soltero JM, Margolina A
Approved by the EMA in 2020 and available on NHS prescription as monotherapy or combination therapy for inadequately controlled type 2 diabetes
Key safety signals observed in the Phase 2 trial included gastrointestinal adverse effects (nausea, vomiting, diarrhoea, and constipation), increases in resting heart rate, and gallbladder-related events consistent with the broader class of incretin-based therapies
It works by enhancing insulin secretion, slowing gastric emptying, and reducing appetite
L-Carnitina Magnesio Citrato: Es una sal de Carnitina que la contiene en un 40%, se usa sobre todo en tabletas efervescentes, en bebidas y barritas